Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.

Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: A scintillator for imaging using X-rays or gamma rays or charged particles, includes a network of glass capillaries with an inner diameter no greater than 500 micrometers. The capillaries are filled with a polymer material made up of at least: (i) a monomer selected from the group including vinyltoluene, styrene and vinylxylene and the isomers thereof, (ii) a cross-linking agent made up of a dimethacrylate having a central chain which includes 1 to 12 carbon atoms, and (iii) lead dimethacrylate. The cross-linking agent is provided to make up 17 wt % to 60 wt % of the mixture thereof with the monomer, and the lead dimethacrylate makes up at least 5 wt %. The cross-linking agent is provided in a ratio of 1.75 to 2.25 times the weight content of the lead dimethacrylate.

Abstract: A scintillator for imaging using X-rays or gamma rays or charged particles, includes a network of glass capillaries with an inner diameter no greater than 500 micrometers. The capillaries are filled with a polymer material made up of at least: (i) a monomer selected from the group including vinyltoluene, styrene and vinylxylene and the isomers thereof, (ii) a cross-linking agent made up of a dimethacrylate having a central chain which includes 1 to 12 carbon atoms, and (iii) lead dimethacrylate. The cross-linking agent is provided to make up 17 wt % to 60 wt % of the mixture thereof with the monomer, and the lead dimethacrylate makes up at least 5 wt %. The cross-linking agent is provided in a ratio of 1.75 to 2.25 times the weight content of the lead dimethacrylate.

Abstract: A scintillator for imaging using X-rays or gamma rays or charged particles, includes a network of glass capillaries with an inner diameter no greater than 500 micrometres. The capillaries are filled with a polymer material made up of at least (i) a monomer selected from the group comprising vinyltoluene, styrene and vinylxylene and the isomers thereof, (ii) a cross-linking agent made up of a divinylbenzene or a dimethacrylate having a central chain which includes 1 to 12 carbon atoms, and (iii) triphenylbismuth. The cross-linking agent is provided to make up 10 wt % to 60% wt of the mixture thereof with the monomer, and the triphenylbismuth makes up at least 5 wt %. The cross-linking agent is provided in a ratio of 0.75 to 2.25 times the weight content of the triphenylbismuth.

Abstract: A scintillator for imaging using X-rays or gamma rays or charged particles, includes a network of glass capillaries with an inner diameter no greater than 500 micrometers. The capillaries are filled with a polymer material made up of at least (i) a monomer selected from the group comprising vinyltoluene, styrene and vinylxylene and the isomers thereof, (ii) a cross-linking agent made up of a divinylbenzene or a dimethacrylate having a central chain which includes 1 to 12 carbon atoms, and (iii) triphenylbismuth. The cross-linking agent is provided to make up 10 wt % to 60% wt of the mixture thereof with the monomer, and the triphenylbismuth makes up at least 5 wt %. The cross-linking agent is provided in a ratio of 0.75 to 2.25 times the weight content of the triphenylbismuth.